IBDEI1LW ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.4)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.4)
 ;;=^IBE(358.4,
 ;;^UTILITY(U,$J,358.4,0)
 ;;=IMP/EXP SELECTION GROUP^358.4I^1190^1190
 ;;^UTILITY(U,$J,358.4,1,0)
 ;;=NEW PATIENT^2^1
 ;;^UTILITY(U,$J,358.4,2,0)
 ;;=ESTABLISHED PATIENT^1^1
 ;;^UTILITY(U,$J,358.4,3,0)
 ;;=CONSULTATIONS^3^1
 ;;^UTILITY(U,$J,358.4,4,0)
 ;;=ALLERGY DIAGNOSES^1^2
 ;;^UTILITY(U,$J,358.4,5,0)
 ;;=IMMUNODEFICIENCY^2^2
 ;;^UTILITY(U,$J,358.4,6,0)
 ;;=OTHER^3^2
 ;;^UTILITY(U,$J,358.4,7,0)
 ;;=IMMUNIZATION^4^3
 ;;^UTILITY(U,$J,358.4,8,0)
 ;;=SKIN TEST^9^3
 ;;^UTILITY(U,$J,358.4,9,0)
 ;;=ALLERGENIC EXTRACT^1^3
 ;;^UTILITY(U,$J,358.4,10,0)
 ;;=PATCH TESTS^8^3
 ;;^UTILITY(U,$J,358.4,11,0)
 ;;=ALLERGY INJECTION/EXTRACT^2^3
 ;;^UTILITY(U,$J,358.4,12,0)
 ;;=LABORATORY^6^3
 ;;^UTILITY(U,$J,358.4,13,0)
 ;;=INFUSIONS^5^3
 ;;^UTILITY(U,$J,358.4,14,0)
 ;;=OTHER^7^3
 ;;^UTILITY(U,$J,358.4,15,0)
 ;;=SPECIAL SERVICES^7^4
 ;;^UTILITY(U,$J,358.4,16,0)
 ;;=TREATMENT^8^4
 ;;^UTILITY(U,$J,358.4,17,0)
 ;;=MISCELLANEOUS^4^4
 ;;^UTILITY(U,$J,358.4,18,0)
 ;;=IMMUNIZATIONS^3^4
 ;;^UTILITY(U,$J,358.4,19,0)
 ;;=CHEMO ADMINISTRATION^1^4
 ;;^UTILITY(U,$J,358.4,20,0)
 ;;=CHEMO DRUGS^2^4
 ;;^UTILITY(U,$J,358.4,21,0)
 ;;=OTHER DRUGS^5^4
 ;;^UTILITY(U,$J,358.4,22,0)
 ;;=PROLONGED SERVICES^6^4
 ;;^UTILITY(U,$J,358.4,23,0)
 ;;=NEW PATIENT^2^5
 ;;^UTILITY(U,$J,358.4,24,0)
 ;;=ESTABLISHED PATIENT^1^5
 ;;^UTILITY(U,$J,358.4,25,0)
 ;;=CONSULTATIONS^3^5
 ;;^UTILITY(U,$J,358.4,26,0)
 ;;=POST OP^4^5
 ;;^UTILITY(U,$J,358.4,27,0)
 ;;=ANEMIA^2^6
 ;;^UTILITY(U,$J,358.4,28,0)
 ;;=BREAST & GYN NEOPLASMS^2^6
 ;;^UTILITY(U,$J,358.4,29,0)
 ;;=COAGULATION DISORDERS^3^6
 ;;^UTILITY(U,$J,358.4,30,0)
 ;;=COUNSELING & SCREENING^4^6
 ;;^UTILITY(U,$J,358.4,31,0)
 ;;=GENITOURINARY NEOPLASMS^5^6
 ;;^UTILITY(U,$J,358.4,32,0)
 ;;=GI CANCER^6^6
 ;;^UTILITY(U,$J,358.4,33,0)
 ;;=HEAD/NECK/LUNG CANCER^7^6
 ;;^UTILITY(U,$J,358.4,34,0)
 ;;=HEMOGLOBINOPATHIES^9^6
 ;;^UTILITY(U,$J,358.4,35,0)
 ;;=LYMPHOID NEOPLASMS^10^6
 ;;^UTILITY(U,$J,358.4,36,0)
 ;;=METASTATIC SITES^11^6
 ;;^UTILITY(U,$J,358.4,37,0)
 ;;=MISC. NEOPLASMS^12^6
 ;;^UTILITY(U,$J,358.4,38,0)
 ;;=MYELOID NEOPLASMS/DISORDERS^13^6
 ;;^UTILITY(U,$J,358.4,39,0)
 ;;=PERSONAL HX OF CANCER^15^6
 ;;^UTILITY(U,$J,358.4,40,0)
 ;;=OTHER^14^6
 ;;^UTILITY(U,$J,358.4,41,0)
 ;;=HEMATOLOGICAL^8^6
 ;;^UTILITY(U,$J,358.4,42,0)
 ;;=SYMPTOMS^17^6
 ;;^UTILITY(U,$J,358.4,43,0)
 ;;=TREATMENT^18^6
 ;;^UTILITY(U,$J,358.4,44,0)
 ;;=SUICIDE IDEATIONS/ATTEMPTS^16^6
 ;;^UTILITY(U,$J,358.4,45,0)
 ;;=ABNORMAL LAB TEST RESULTS^1^6
 ;;^UTILITY(U,$J,358.4,46,0)
 ;;=SPECIAL SERVICES^10^7
 ;;^UTILITY(U,$J,358.4,47,0)
 ;;=CHEMO NURSE PROCEDURES^2^7
 ;;^UTILITY(U,$J,358.4,48,0)
 ;;=INFUSION DRUGS^7^7
 ;;^UTILITY(U,$J,358.4,49,0)
 ;;=BLOOD PRODUCTS^1^7
 ;;^UTILITY(U,$J,358.4,50,0)
 ;;=DIAGNOSTIC PROCEDURES^3^7
 ;;^UTILITY(U,$J,358.4,51,0)
 ;;=OTHER DRUGS^8^7
 ;;^UTILITY(U,$J,358.4,52,0)
 ;;=IMMUNIZATION ADMINISTRATION^5^7
 ;;^UTILITY(U,$J,358.4,53,0)
 ;;=IMMUNIZATIONS^6^7
 ;;^UTILITY(U,$J,358.4,54,0)
 ;;=PROLONGED SVC-MD/NP/PA^9^7
 ;;^UTILITY(U,$J,358.4,55,0)
 ;;=EDUCATION/TRAINING^4^7
 ;;^UTILITY(U,$J,358.4,56,0)
 ;;=NEW PATIENT^2^8
 ;;^UTILITY(U,$J,358.4,57,0)
 ;;=ESTABLISHED PATIENT^1^8
 ;;^UTILITY(U,$J,358.4,58,0)
 ;;=CONSULTATIONS^3^8
 ;;^UTILITY(U,$J,358.4,59,0)
 ;;=COMPLEX CHRONIC CARE^4^8
 ;;^UTILITY(U,$J,358.4,60,0)
 ;;=ANEMIA^1^9
 ;;^UTILITY(U,$J,358.4,61,0)
 ;;=ARTIFICIAL OPENING STATUS^2^9
